新生儿疾病干细胞疗法翻译中的障碍。

Barriers in translating stem cell therapies for neonatal diseases.

作者信息

Damianos Andreas, Sammour Ibrahim

机构信息

Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, Ohio.

Riley Hospital for Children, Indiana University, Indianapolis, USA.

出版信息

Semin Perinatol. 2023 Apr;47(3):151731. doi: 10.1016/j.semperi.2023.151731. Epub 2023 Mar 16.

DOI:10.1016/j.semperi.2023.151731

PMID:36990922

Abstract

Over the last 20 years, stem cells of varying origin and their associated secretome have been investigated as a therapeutic option for a myriad of neonatal models of disease, with very promising results. Despite the devastating nature of some of these disorders, translation of the preclinical evidence to the bedside has been slow. In this review, we explore the existing clinical evidence for stem cell therapies in neonates, highlight the barriers faced by researchers and suggest potential solutions to move the field forward.

摘要

在过去20年中，不同来源的干细胞及其相关分泌组已被作为多种新生儿疾病模型的治疗选择进行研究，结果非常有前景。尽管其中一些疾病具有毁灭性，但临床前证据向临床应用的转化却很缓慢。在本综述中，我们探讨了新生儿干细胞治疗的现有临床证据，强调了研究人员面临的障碍，并提出了推动该领域发展的潜在解决方案。